Dr Hans Wildiers talks to ecancer at the 2013 European Cancer Congress about TDM1, a new class of anti-HER2 therapy, trastuzumab, DM1 and a linker.

The study looked at patients with advanced breast cancer who had previously been treated for the metastatic disease. Results from the study show that patients respond better to TDM1 than the classical course of chemotherapy.

ecancer's filming at ECC has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.